AI-Driven Glucose Biosensing: Dexcom's (DXCM) Path To A Comeback
Dexcom has become the first company to launch a generative AI-powered continuous glucose monitor.
Dexcom Inc (DXCM)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 2,429,523 | $162,875,222 | +6698% | 0.13% |
| 2. | Citadel Investment Group Ken Griffin | 1,233,844 | $82,716,902 | +70% | 0.01% |
| 3. | 92,700,000 | $82,271,250 | +13% | 2.33% | |
| 4. | 1,217,200 | $81,601,088 | +193% | 0.01% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,143,476 | $76,658,631 | +183% | 0.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.01 | 25,000 | Director | 58,502 | 2017-11-07 | Filing | |
| $49.61 | 10,000 | Director | 33,502 | 2017-11-06 | Filing | |
| $15.50 | 70,000 | Director | 121,975 | 2013-03-11 | Filing | |
| $10.37 | 1,000 | Director | 6,000 | 2012-03-08 | Filing | |
| $10.34 | 1,000 | Director | 5,000 | 2012-03-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $76.87 | 424 | Officer | 70,768 | 2024-12-16 | Filing | |
| $76.87 | 744 | Officer | 80,030 | 2024-12-16 | Filing | |
| $76.87 | 744 | Officer | 264,171 | 2024-12-16 | Filing | |
| $76.87 | 1,000 | Director | 23,349 | 2024-12-16 | Filing | |
| $74.73 | 4,259 | Officer | 71,192 | 2024-11-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 44,467,463 | $5,517,967,483 | 0.12% | |
| 2. | 32,726,186 | $4,060,992,422 | 0.1% | |
| 3. | 16,520,313 | $2,050,005,640 | 1.69% | |
| 4. | 16,198,598 | $2,010,084,026 | 0.09% | |
| 5. | 15,296,032 | $1,898,085,347 | 0.46% |
News See All
12 Best Weight Loss Stocks to Buy According to Hedge Funds
Most people have at some point sought to include weight loss and physical exercise in their daily life.
10 Worst Performing Healthcare Stocks in 2024
The healthcare industry remains a vital and resilient sector which is driven by advancements in technology, increasing global demand, and an aging population.
Wells Fargo's Best Growth Stocks: 28 Stocks With The Highest Consensus EPS Growth Estimates
With the interest rate cycle kicking off in the US, stocks that are exposed to consumer and business spending are starting to see a favorable economic outlook.
Here’s Why DexCom (DXCM) Declined In Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
12 High Growth Large Cap Stocks to Buy Now
BlackRock highlighted that its portfolio managers are broadly optimistic about US equities.
DexCom (DXCM) Fell Due to an Uncharacteristic Earnings Miss
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” third quarter 2024 investor letter. A copy of the letter can be downloaded here. The U.S.
Here's Why DexCom (DXCM) Detracted in Q3
Investment advisory firm Ithaka Group released the “Ithaka US Growth Strategy” third-quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Worst Performing Stocks in S&P 500 in 2024
Since 2023, the market has experienced extended winning streaks, reflecting the economy's resilience.
Multiple Headwinds Dragged DexCom (DXCM) in Q3
Baron Funds, an investment management company, released its “Baron Asset Fund” third quarter 2024 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
